Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Migraine

Lasmiditan

Brand names: Reyvow

Lasmiditan is a selective serotonin 5-HT1F receptor agonist (a ditan) used for the acute treatment of migraine with or without aura.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It activates 5-HT1F receptors to inhibit trigeminal nociceptive signalling and neuropeptide release, relieving migraine without causing the vasoconstriction associated with triptans.

Prescribing in practice

  • It impairs the ability to drive, so patients must not drive or operate machinery for several hours after each dose owing to dizziness and sedation.
  • Because it crosses the blood-brain barrier and acts centrally, central nervous system effects such as somnolence and paraesthesia are common.
  • Caution and dose review are advised when combined with other serotonergic or CNS-depressant medicines.

Monitoring

No routine laboratory monitoring is required, but assess migraine response and central nervous system adverse effects clinically.

Counselling the patient

  • Do not drive or operate machinery for the period specified after taking a dose.
  • Avoid alcohol, which can worsen drowsiness.
  • Tell your clinician about all medicines that affect serotonin or cause sleepiness.

Evidence & guidelines

Lasmiditan is licensed for acute migraine on the basis of randomised trials showing pain freedom without the vascular contraindications of triptans.

Reference: SAMURAI trial NEJM 2019; 381(23):2230-2241; SPARTAN trial NEJM 2019; 381(23):2245-2256; MHRA SPC; EAN Migraine Guidelines 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways